Biomatrix (US) regains European marketing rights to Synvisc
This article was originally published in Clinica
Biomatrix (US) is to reacquire European marketing rights from Roche to the hylan polymer treatment for osteoarthritis, Synvisc. Roche will retain exclusive marketing rights in Sweden and South Africa. The agreement coincides with Biomatrix' CE marking of the elastoviscous product which is injected into the knee joint.